Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP

Citations Over TimeTop 10% of 2013 papers

Abstract

Among epigenetic "writers", "readers", and "erasers", the lysine methyltransferases G9a and GLP, which catalyze mono- and dimethylation of histone H3 lysine 9 (H3K9me2) and nonhistone proteins, have been implicated in a variety of human diseases. A "toolkit" of well-characterized chemical probes will allow biological and disease hypotheses concerning these proteins to be tested in cell-based and animal models with high confidence. We previously discovered potent and selective G9a/GLP inhibitors including the cellular chemical probe UNC0638, which displays an excellent separation of functional potency and cell toxicity. However, this inhibitor is not suitable for animal studies due to its poor pharmacokinetic (PK) properties. Here, we report the discovery of the first G9a and GLP in vivo chemical probe UNC0642, which not only maintains high in vitro and cellular potency, low cell toxicity, and excellent selectivity, but also displays improved in vivo PK properties, making it suitable for animal studies.

Related Papers

• → Uncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels(2023)39 cited
• → The potency of bovine PPD tuberculins in guinea-pigs and in tuberculous cattle(1983)18 cited
• → Establishment of a Potency Test by ELISA for a Rabies Vaccine for Animal Use in Japan(2003)15 cited
• → Potency analysis of cellular therapies: the role of molecular assays(2021)
• → Application of Emax model to assess the potency of topical corticosteroid products(2022)